01—Abstract
Summary
Summary of the 10-Q filed October 30, 2024. Cited figures are marked; the original filing is the authoritative source.
Stryker Corporation reported a strong third quarter for fiscal year 2024, demonstrating robust top-line growth and improved profitability.
Net sales increased by 11.9%a year-over-year, driven by solid performance in both the MedSurg and Neurotechnology, and Orthopaedics and Spine segments, with particularly strong unit volume increases across most product lines. The company also showed improved operational efficiency, with operating income growing faster than net sales. Net earnings per diluted share rose by 20.0% year-over-year.
Stryker continued to invest in growth through strategic acquisitions and development, while also managing its financial leverage effectively through debt issuance and managing cash flow from operations. Investors should note the company's ongoing focus on innovation and strategic M&A as key drivers of future performance, alongside the management's confidence in its financial health and ability to meet liquidity needs.
02—Key points
Key Highlights
- Stryker reported a 11.9% increase in net sales for Q3 2024, reaching $5,494 million, with organic growth (excluding acquisitions/divestitures and currency impacts) of 10.3% in constant currency.
- Net earnings increased by 20.5% to $834 million for the quarter, with diluted EPS growing 20.0% to $2.16.
- Operating income grew by 16.5% to $1,085 million, indicating improved operational leverage as operating income margin expanded to 19.7% from 19.0% in the prior year.
- The MedSurg and Neurotechnology segment saw sales growth of 12.8%, while Orthopaedics and Spine grew by 10.7%, showcasing broad-based strength.
- The company completed significant acquisitions in the first nine months of 2024, with a total consideration of $1,598 million, net of cash acquired, demonstrating continued M&A activity to expand product portfolios.
- Stryker maintained a strong balance sheet with $3,850 million in cash and cash equivalents and $750 million in short-term investments, and ended the quarter with current assets exceeding current liabilities by $7,004 million.
- The company issued new senior unsecured notes totaling $1.5 billion and €1.4 billion in September 2024, strengthening its financial position and extending debt maturities.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q3 FY2024, Stryker Corp kept $0.15.
- Revenue$5.49B100.0%
- Cost of revenue−$1.98B36.0%
- Gross profit$3.52B64.0%
- Operating costs−$2.43B44.3%
- Operating income$1.08B19.7%
- Interest, other & tax−$251.0M4.6%
- Net income$834.0M15.2%
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 30, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $5.49B$4.91B | +11.9% |
| Cost of Revenue | $1.98B$1.75B | +12.9% |
| Gross Profit | $3.52B$3.16B | +11.4% |
| R&D Expenses | $377.00M$353.00M | +6.8% |
| SG&A Expenses | $1.89B$1.71B | +10.8% |
| Operating Expenses | $2.43B$2.23B | +9.2% |
| Operating Income | $1.08B$931.00M | +16.5% |
| Interest Expense | $98.00M— | — |
| Net Income | $834.00M$692.00M | +20.5% |
| EPS (Basic) | $2.18$1.82 | +19.8% |
| EPS (Diluted) | $2.16$1.80 | +20.0% |
| Shares Outstanding (Basic) | 381.10M379.80M | +0.3% |
| Shares Outstanding (Diluted) | 385.60M384.00M | +0.4% |
05—Questions
Frequently Asked Questions
What were the primary drivers of Stryker's sales growth in the third quarter of 2024?
Stryker's sales growth in Q3 2024 was primarily driven by a combination of increased unit volume across its MedSurg and Neurotechnology and Orthopaedics and Spine segments, along with a smaller contribution from higher pricing. Excluding acquisitions, divestitures, and currency impacts, organic sales grew by 10.3% in constant currency, indicating strong underlying business performance.
How did Stryker's profitability perform in the third quarter?
Profitability improved in Q3 2024. Net earnings increased by 20.5% to $834 million, and diluted Earnings Per Share (EPS) grew by 20.0% to $2.16. The operating income margin also expanded to 19.7% from 19.0% in the prior year, reflecting effective cost management and operating leverage.
What is Stryker's current financial position and liquidity outlook?
Stryker maintains a strong financial position with robust liquidity. As of September 30, 2024, the company held $3,850 million in cash and cash equivalents and $750 million in short-term investments. Current assets significantly exceeded current liabilities, and the company anticipates supporting its operating needs through cash from operations, commercial paper, and existing credit lines. They also recently issued new debt, further enhancing their financial flexibility.
Has Stryker been active in mergers and acquisitions, and how does this impact the business?
Yes, Stryker has been active in M&A. In the first nine months of 2024, they completed various acquisitions for a total consideration of $1,598 million, net of cash acquired, with additional contingent consideration. These acquisitions are aimed at expanding product portfolios and strategic market presence, contributing to reported sales growth.
06—Continue